AstraZeneca PLC

6-K ADMISSION OF FURTHER SECURITIES TO TRADING Aug 3, 2026 6-K TOTAL VOTING RIGHTS Aug 3, 2026 6-K DATROWAY APPROVED IN EU FOR TNBC Jul 31, 2026 6-K FORM 6-K Jul 27, 2026 6-K UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA Jul 27, 2026 6-K SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS Jul 27, 2026 6-K ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER Jul 23, 2026 6-K ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR Jul 14, 2026 6-K UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL Jul 9, 2026 6-K ADMISSION OF FURTHER SECURITIES TO TRADING Jul 1, 2026 6-K TOTAL VOTING RIGHTS Jul 1, 2026 6-K ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS Jun 29, 2026 6-K DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC Jun 29, 2026 6-K TRUQAP APPROVED IN US FOR PROSTATE CANCER Jun 15, 2026 6-K ADMISSION OF FURTHER SECURITIES TO TRADING Jun 1, 2026 6-K TOTAL VOTING RIGHTS Jun 1, 2026 6-K IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER May 29, 2026 6-K US FDA DECISION DATE ON CAMIZESTRANT EXTENDED May 27, 2026 6-K DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC May 26, 2026 6-K ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS May 26, 2026 6-K CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU May 26, 2026 6-K DIRECTOR/PDMR SHAREHOLDING May 18, 2026 6-K BAXFENDY APPROVED IN THE US FOR HYPERTENSION May 18, 2026 6-K ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS May 18, 2026 6-K IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER May 14, 2026 6-K TOTAL VOTING RIGHTS AND ADMISSION OF SHARES May 1, 2026 6-K FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER May 1, 2026 6-K FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER May 1, 2026 6-K 1ST QUARTER RESULTS Apr 29, 2026 6-K BREZTRI APPROVED IN THE US FOR ASTHMA Apr 28, 2026 6-K SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US Apr 27, 2026 6-K DIRECTORATE CHANGE Apr 23, 2026 6-K I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT Apr 21, 2026 6-K THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD Apr 20, 2026 6-K RESULT OF AGM Apr 9, 2026 6-K IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER Apr 2, 2026 6-K TOTAL VOTING RIGHTS AND ADMISSION OF SHARES Apr 1, 2026 6-K EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS Mar 31, 2026 6-K TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS Mar 27, 2026 6-K NOTIFICATION OF ADMISSION OF SHARES Mar 20, 2026